科兴制药亮相CPHI并圆满举办国际医药高端论坛暨科兴制药全球化系列活动

Core Viewpoint - The annual pharmaceutical industry event, CPHI&PMEC China 2025, showcased the comprehensive strength and value advantages of the company's overseas commercialization platform, receiving positive feedback from domestic and international guests [1][2] Group 1: Company Strategy and Development - The company is advancing its "innovation + internationalization" strategy, rapidly progressing in drug research and overseas commercialization, and has established partnerships with several well-known pharmaceutical companies for international collaboration [2] - The company aims to provide superior drugs and comprehensive solutions for global patients by collaborating with outstanding domestic pharmaceutical and medical device enterprises [2] Group 2: Event Highlights - During the CPHI exhibition from June 24 to 26, the company showcased over 20 high-quality drugs, synthetic biology, and medical beauty products, facilitating discussions on its innovative drug pipeline and overseas commercialization with both new and existing clients [2] - The company emphasized its confidence and achievements in overseas business during the forum, highlighting its strategic layout, core advantages in research, production, and sales, as well as its development plans for international markets [2] Group 3: Global Engagement - The company hosted the second "Global Sharing, Co-creating the Future" 2025 International Pharmaceutical High-end Forum, engaging in deep industry dialogue with global clients and partners from 20 countries, including Brazil, Colombia, Saudi Arabia, and Indonesia [2] - The company’s platform for international expansion will continue to be driven by innovation and collaboration, aiming to empower more Chinese pharmaceutical companies to enter international markets [2]